Ovarian / Fallopian / Peritoneal

Relapsed or Refractory Intolerant to Standard Care
  ▶ Part 1A Only
    ▶ CCT5048 Phase I Open Label Dose Escalation Study of CRX109 in Advanced Solid Tumors
      ▶ PI: Dorigo Sponsor: BioEclipse Therapeutics
        1st Priority
    ▶ VAR0243 Phase II Study to Evaluate the Safety Pharmacokinetics and Efficacy of BLU-222 as Single Agent and in Combination Therapy in Advanced Solid Tumors
      ▶ PI: Telli Sponsor: Blueprint Medicines Corporation
    ▶ ECOG-ACRIN EAY191-N4 Randomized Trial of Seipelatinib & Olaparib or Seipelatinib Alone in Recurrent or Persistent RAS Pathway Mutant Ovarian and Endometrial Cancers: A ComboMATCH Treatment Trial
      ▶ PI: Chow Sponsor: National Cancer Institute (NCI)
    ▶ GYNOPF0018 Phase III Study of Relocorilant in Combination w/ Nab-Paclitaxel vs Nab-Paclitaxel Monotherapy in Advanced Platinum-Resistant High-Grade Epithelial Ovarian Primary Peritoneal or Fallopian- Tube Cancer (ROSELLA)
      ▶ PI: Dorigo Sponsor: Concept Therapeutics Incorporated
    ▶ GYNOVA0056 Phase IIb Single Arm Study of Maveroepimut-S and Low-Dose Cyclophosphamide in Platinum-Resistant Epithelial Ovarian Cancer (AVALON)
      ▶ PI: Dorigo Sponsor: IMV Inc.
    ▶ VAR0211 Phase II MORAb-202 FolateReceptor Alpha-Targeting Antibody-Drug Conjugate in Selected Tumor Types
      ▶ PI: Berek Sponsor: Eisai Inc.
      2nd Priority
  ▶ Recurrent
    ▶ Platinum Resistant
      ▶ GYNOVA0057 Phase II Trial of Niragacestat in Recurrent Ovarian Granulosa Cell Tumors
        ▶ PI: Dorigo Sponsor: SpringWorks Therapeutics
    ▶ Platinum Resistant or Refractory
      ▶ CCT5088 Phase I Trial of Niragacestat in Recurrent Ovarian Granulosa Cell Tumors
        ▶ PI: Berek Sponsor: ImmuNoGen, Inc.
    ▶ Ovarian Granulosa Cell Tumors
      ▶ Platinum Sensitive
    ▶ VAR0243 Phase II Study to Evaluate the Safety Pharmacokinetics and Efficacy of BLU-222 as Single Agent and in Combination Therapy in Advanced Solid Tumors
      ▶ PI: Telli Sponsor: Blueprint Medicines Corporation
  ▶ Recurrent
    ▶ Platinum Resistant or Refractory
      ▶ Extension Study
        ▶ Immunotherapy

KEY
- Pending
- Open for Enrollment
- Link
- Optional Path
- Trial Posting
- Extension Study
- Immunotherapy
- Enrollment on Hold

Please mark up a copy using black ink and email changes to SRC-office@stanford.edu